Literature DB >> 21577298

Treatment of psychological co-morbidities in common gastrointestinal and hepatologic disorders.

Antonina A Mikocka-Walus1.   

Abstract

Anxiety and depressive disorders frequently coexist with gastrointestinal and hepatologic conditions. Despite their high prevalence, approach to treating these co-morbidities is not always straightforward. This paper aims to review the current literature into etiology of psychological co-morbidities and their treatment in three conditions commonly encountered at gastroenterology outpatient clinics, namely inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and chronic hepatitis C (HepC). The paper demonstrates that although psychotherapy (and cognitive-behavioural therapy in particular) has been established as an effective treatment in IBS, more studies are needed in HepC and IBD. Antidepressants have been recognized as an effective treatment for psychological and somatic symptoms in IBS and for depression in HepC, but good quality studies in IBD are lacking despite the promising preliminary findings from animal models and case studies. Further studies in this area are needed.

Entities:  

Keywords:  Antidepressants; Hepatitis C; Inflammatory bowel disease; Irritable bowel syndrome; Psychological co-morbidities; Psychotherapy

Year:  2010        PMID: 21577298      PMCID: PMC3091146          DOI: 10.4292/wjgpt.v1.i2.64

Source DB:  PubMed          Journal:  World J Gastrointest Pharmacol Ther        ISSN: 2150-5349


  77 in total

1.  British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome.

Authors:  J Jones; J Boorman; P Cann; A Forbes; J Gomborone; K Heaton; P Hungin; D Kumar; G Libby; R Spiller; N Read; D Silk; P Whorwell
Journal:  Gut       Date:  2000-11       Impact factor: 23.059

Review 2.  Controversies surrounding the comorbidity of depression and anxiety in inflammatory bowel disease patients: a literature review.

Authors:  Antonina A Mikocka-Walus; Deborah A Turnbull; Nicole T Moulding; Ian G Wilson; Jane M Andrews; Gerald J Holtmann
Journal:  Inflamm Bowel Dis       Date:  2007-02       Impact factor: 5.325

Review 3.  Inflammatory bowel disease: current therapeutic options.

Authors:  Eugeni Domènech
Journal:  Digestion       Date:  2006-02-08       Impact factor: 3.216

Review 4.  Hepatitis C virus infection in the United States.

Authors:  M J Alter
Journal:  J Hepatol       Date:  1999       Impact factor: 25.083

5.  Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey.

Authors:  R C Kessler; C B Nelson; K A McGonagle; J Liu; M Swartz; D G Blazer
Journal:  Br J Psychiatry Suppl       Date:  1996-06

6.  Evaluation of a psychological treatment for inflammatory bowel disease.

Authors:  S P Schwarz; E B Blanchard
Journal:  Behav Res Ther       Date:  1991

7.  The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome.

Authors:  Francis Creed; Lakshmi Fernandes; Elspeth Guthrie; Stephen Palmer; Joy Ratcliffe; Nicholas Read; Christine Rigby; David Thompson; Barbara Tomenson
Journal:  Gastroenterology       Date:  2003-02       Impact factor: 22.682

8.  The epidemiology of inflammatory bowel disease: a large, population-based study in Sweden.

Authors:  A Ekbom; C Helmick; M Zack; H O Adami
Journal:  Gastroenterology       Date:  1991-02       Impact factor: 22.682

9.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

Review 10.  Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis.

Authors:  A C Ford; N J Talley; P S Schoenfeld; E M M Quigley; P Moayyedi
Journal:  Gut       Date:  2008-11-10       Impact factor: 23.059

View more
  5 in total

Review 1.  A Review of Inflammatory Bowel Disease: A Model of Microbial, Immune and Neuropsychological Integration.

Authors:  P Tavakoli; U Vollmer-Conna; D Hadzi-Pavlovic; M C Grimm
Journal:  Public Health Rev       Date:  2021-05-05

2.  Psychological issues in inflammatory bowel disease: an overview.

Authors:  M S Sajadinejad; K Asgari; H Molavi; M Kalantari; P Adibi
Journal:  Gastroenterol Res Pract       Date:  2012-06-21       Impact factor: 2.260

3.  Ketamine interactions with gut-microbiota in rats: relevance to its antidepressant and anti-inflammatory properties.

Authors:  Bruk Getachew; Joseph I Aubee; Richard S Schottenfeld; Antonei B Csoka; Karl M Thompson; Yousef Tizabi
Journal:  BMC Microbiol       Date:  2018-12-22       Impact factor: 3.605

4.  Psychopharmacological treatment and psychological interventions in irritable bowel syndrome.

Authors:  Emanuele Sinagra; Claudia Romano; Mario Cottone
Journal:  Gastroenterol Res Pract       Date:  2012-08-22       Impact factor: 2.260

5.  Effects of C-Terminal Domain of the Heavy Chain of Tetanus Toxin on Gut Microbiota in a Rat Model of Depression.

Authors:  Bruk Getachew; Yousef Tizabi
Journal:  Clin Pharmacol Transl Med       Date:  2019-10-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.